Nxera Pharma's FY2024 Financial Results: A Promising Pipeline and Strong Growth Ahead

Nxera Pharma Co. Ltd (Nxera; TSE 4565) is set to announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025. The Company will host a live webinar presentation with key executives, including Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, President of Nxera Pharma UK and Head of UK R&D, and Makoto Sugita, President of Nxera Pharma Japan and Chief Medical Officer. The webinar is open to all existing and potential investors, as well as sell-/buy-side analysts, and will consist of a presentation followed by a Q&A session.

Nxera Pharma is a technology-powered biopharma company focused on developing new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The company's core activities include drug discovery, drug development, and the commercialization of pharmaceutical products. With over 350 talented employees at key locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, Nxera Pharma is listed on the Tokyo Stock Exchange (ticker: 4565).



Nxera Pharma's extensive pipeline consists of over 30 active programs from discovery through to late clinical stage, internally and in partnership with leading pharma and biotech companies. The pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases. The company leverages its unique and industry-leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.

Nxera Pharma's revenue growth trajectory has been significant over the past year, with a year-on-year increase of 301.6% from the nine-month period ended September 30, 2023, to the same period in 2024. This growth can be attributed to several key drivers, including the expansion of the product pipeline, commercialization of products in Japan, strategic partnerships and collaborations, and investment in research and development. The company's core operating profit has also increased significantly, driven by the revenue growth and efficient use of the NxWave™ platform.



As Nxera Pharma continues to advance its pipeline and expand its global presence, investors can expect strong growth and promising developments in the coming years. The company's focus on addressing major unmet needs in various therapeutic areas, combined with its efficient use of the NxWave™ platform, positions Nxera Pharma well for long-term success. As the company presents its FY2024 financial results and operational highlights, investors will have the opportunity to gain valuable insights into its progress and future prospects.



In conclusion, Nxera Pharma's FY2024 financial results webinar presentation offers an exciting opportunity for investors to learn more about the company's strong performance, promising pipeline, and growth prospects. With a focus on addressing major unmet needs in various therapeutic areas and leveraging its unique NxWave™ platform, Nxera Pharma is well-positioned for long-term success. As the company continues to advance its pipeline and expand its global presence, investors can expect strong growth and promising developments in the coming years.